Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enfuvirtide.

Jacob P Lalezari1, Andrew D Luber

  • 1Quest Clinical Research, and University of California at San Francisco, Mount Zion Hospital, San Francisco, California, USA. drjay@questclinical.com

Drugs of Today (Barcelona, Spain : 1998)
|May 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load.

The Journal of infectious diseases·2026
Same author

Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV.

Contemporary clinical trials·2025
Same author

Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study.

Nature medicine·2025
Same author

Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial.

Journal of acquired immune deficiency syndromes (1999)·2025
Same author

A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.

Clinical therapeutics·2024
Same author

A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses.

JCI insight·2024
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Enfuvirtide (T-20) is a novel fusion inhibitor that effectively blocks HIV-1 entry into host cells. Clinical studies confirm its safety and efficacy in treating both adult and pediatric HIV-1 patients, including those with resistant strains.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • HIV-1 entry into host cells is a critical step in viral replication.
  • Developing effective antiretroviral therapies for multi-drug resistant HIV-1 remains a challenge.

Purpose of the Study:

  • To evaluate the efficacy and safety of enfuvirtide (T-20), a novel fusion inhibitor.
  • To assess the pharmacokinetic profile and clinical effectiveness of enfuvirtide in HIV-1-positive patients.

Main Methods:

  • In vitro and in vivo studies were conducted to assess antiretroviral activity.
  • Phase II and III clinical trials evaluated enfuvirtide in adult and pediatric populations.
  • Pharmacokinetic studies examined dosing frequency and drug behavior in patients.

Related Experiment Videos

Main Results:

  • Enfuvirtide demonstrated potent antiretroviral activity against HIV-1, including multi-drug resistant strains.
  • Subcutaneous administration allows for twice-daily dosing, with potential for once-daily administration.
  • Clinical studies confirmed enfuvirtide as an effective and safe treatment option.

Conclusions:

  • Enfuvirtide represents a new class of antiretroviral agents (fusion inhibitors).
  • The drug is effective and well-tolerated in both adult and pediatric HIV-1 patients.
  • Enfuvirtide offers a valuable therapeutic option for managing HIV-1 infection.